Special Issue

Personalized Medicine for Cardiovascular Disease

Message from the Guest Editor

Rapid progress in healthcare IT provides new chances to expand our data collection and its analysis. Through big data analytics and artificial intelligence (AI), researchers can build novel personalized and actionable applications for patients with cardiovascular disease.Recently, biometric data, patient-reported data, internet-driven data and multi-omics data have grown rapidly. Taken together, a movement toward more comprehensive and integrated analytics is emerging.In this Special Issue, we aim to focus on practical works or products related to (1) the building of big data infrastructures (data sources), and (2) the development and implementation of personalized algorithms and applications in the cardiovascular field. This includes administrative databases, clinical registries, and electronic health records, as well as a broad range of omics data. We invite innovative, reproducible, and open research, and practical research that can ultimately help patients. We are open to original articles, metaanalyses, reviews, and policy proposals, as long as they fit the scope of the Special Issue.

Guest Editor

Dr. Hyung Joon Joo Department of Cardiology, Cardiovascular Center, College of Medicine, Korea University, Seoul 02841, Republic of Korea

Deadline for manuscript submissions

closed (20 December 2020)

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/54706

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).